TRIF alone promotes type-I IFN signaling and strengthens CD8+ T cell priming, activates NF-κB and IRF3, induces DAMP release and necroptotic tumor cell deathCo-administration of TLR3 agonists with anti-CTLA-4 or anti-LAG-3 enhances vaccine-mediated tumor suppression. This evidence concerns the gene IRF3 and neoplasm.